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Soy protein is an important component of soybeans and provides an abundant source of dietary protein. Among 
the dietary proteins, soy protein is considered a complete protein in that it contains ample amounts of all the 
essential amino acids plus several other macronutrients with a nutritional value roughly equivalent to that of 
animal protein of high biological value. Soy protein is unique among the plant-based proteins because it is asso-
ciated with isoflavones, a group of compounds with a variety of biological properties that may potentially bene-
fit human health. An increasing body of literature suggests that soy protein and its isoflavones may have a bene-
ficial role in obesity. Several nutritional intervention studies in animals and humans indicate that consumption 
of soy protein reduces body weight and fat mass in addition to lowering plasma cholesterol and triglycerides. In 
animal models of obesity, soy protein ingestion limits or reduces body fat accumulation and improves insulin 
resistance, the hallmark of human obesity. In obese humans, dietary soy protein also reduces body weight and 
body fat mass in addition to reducing plasma lipids. Several potential mechanisms whereby soy protein may 
improve insulin resistance and lower body fat and blood lipids are discussed and include a wide spectrum of 
biochemical and molecular activities that favorably affect fatty acid metabolism and cholesterol homeostasis. 
The biologic actions of certain constituents of soy protein, particularly conglycinin, soyasaponins, phospholipids, 
and isoflavones, that relate to obesity are also discussed. In addition, the potential of soy protein in causing food 
allergy in humans is briefly discussed. 
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1.  Introduction 
Obesity has become a worldwide epidemic and 
its prevalence continues to increase at a rapid rate in 
various populations and across all age groups [1-4]. 
Obesity poses a major public health challenge since it 
is a well recognized independent predictor of prema-
ture mortality [5,6]. Moreover, it often coexists with 
other cardiovascular risk factors, namely, diabetes, 
dyslipidemia, and hypertension, which further add to 
the burden of cardiovascular disease. The dramatic 
increase in the occurrence of overweight and obesity 
over the past several decades is attributed in part to 
changes in dietary and lifestyle habits, such as rapidly 
changing diets, increased availability of high-energy 
foods, and reduced physical activity of peoples in both 
developed and developing countries [7].   
  Obesity is a complex metabolic disorder that is 
thought to result from an imbalance of energy intake 
and energy expenditure leading to the excess accu-
mulation of fat in various adipose tissues and organs. 
The development of obesity is associated with hyper-
insulinemia, insulin resistance, and abnormalities in 
lipid metabolism. Insulin resistance is considered the 
most common underlying abnormality in human obe-
sity and is influenced by genetic and environmental 
factors, and in particular, changes in diet and physical 
activity [8,9]. Lipid abnormalities associated with obe-
sity include increased overall production of lipids 
with elevated concentrations of fatty acids, triacyl-
glycerols, and low-density lipoproteins (LDL), as well 
as very-low density lipoproteins (VLDL). Excess sugar 
intake especially in the form of high sugar containing 
and high fructose corn syrup containing colas leads to 
the formation and deposition of lipids in various fatty 
tissues. Elevated plasma concentrations of free fatty 
acids (FFA) have been shown to play a key role in 
contributing to the development of insulin resistance 
in obesity and in type 2 diabetes mellitus [10]. In addi-
tion, there is evidence that suggests that accumulation 
of excess fat and FFAs in non-adipose tissues, such as 
the liver, heart, skeletal muscle, kidneys, and blood 
vessels may impair their functions, and contribute to 
cell dysfunction or cell death, a phenomenon known 
as lipotoxicity [11-13]. Preventive or therapeutic strate-
gies to control obesity should target these abnormali-
ties. Various dietary modifications designed to control 
excess body weight and dyslipidemia have focused on 
the manipulation of the amount and nature dietary 
energy and fat intakes. In recent years, increased at-
tention has shifted toward the role of dietary protein 
intake in the management of obesity. Int. J. Med. Sci. 2007, 4 
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2.  Dietary protein and effects on food intake 
and body weight  
Ingestion of foods with high protein content is 
well known to suppress appetite and food intake in 
humans [14]. Among the three macronutrients (car-
bohydrate, fat, and protein), protein has the most 
suppressing effect on food intake. In addition, dietary 
protein has been shown to induce higher satiating and 
thermogenic effects and greater weight loss than car-
bohydrates [15-17]. In a randomized trial in over-
weight and obese subjects, consumption of high pro-
tein (25% of total energy) in ad libitum fat-reduced 
diets for 6 months produced greater weight loss and 
body fat loss, compared to consumption of high car-
bohydrate (12% of total energy) [15]. These effects 
were not related to changes in fat intake since the 
amount of dietary fat (30% of total energy) was main-
tained constant during the intervention. Similarly, in a 
4-week randomized dietary intervention trial of male 
obese hyperinsulinemic subjects, a high protein 
hypoenergetic diet (45% protein, 25% carbohydrates, 
and 30% fat) also induced greater weight loss and 
resting energy expenditure, compared to a high car-
bohydrate hypoenergetic diet (12% protein, 25% car-
bohydrates, and 30% fat) [16]. In a recent 12-week trial 
conducted in healthy adult subjects, increasing the 
amount of dietary protein content from 15% to 30% of 
total energy while maintaining the carbohydrate con-
tent (50%of total daily caloric intake) in the diet re-
sulted in sustained losses in weight and body fat [17]. 
The favorable effects on body composition in this 
study appear to be due to sustained decrease in appe-
tite and ad libitum caloric intake induced by the 
high-protein intake. More recently, Batterham et al 
examined the effects of dietary protein on satiety and 
the responses of gut hormones, particularly the gut 
hormone peptide YY (PYY), a known inhibitor of food 
intake in humans and rodents [18]. These investigators 
showed that high-protein intake induced an increase 
in plasma PYY levels and marked satiety in nor-
mal-weight and obese human subjects. Furthermore, 
in studies of obese Pyy null mice, which were selec-
tively resistant to the satiating and weight-reducing 
effects of protein, exogenous administration of PYY in 
these animals reversed their obesity. These findings 
suggest that modulating the release of endogenous 
satiety factors, such as PYY treatment, plays an im-
portant role in mediating the satiating effects of die-
tary protein. 
The source or type of dietary protein also has 
been shown to have an influence on the magnitude of 
food intake suppression and energy expenditure, as 
well as on insulin sensitivity [19-22]. Hurley et al. [19] 
examined the metabolic effects of varying dietary 
protein and carbohydrate source in rats. These inves-
tigators fed male Sprague-Dawley rats for 28 days 
with semi-purified diets that varied in both protein 
and carbohydrate sources, namely, soy protein isolate 
(SPI)-cornstarch, SPI-sucrose, cod protein 
(COD)-cornstarch, COD-sucrose, casein- 
(CAS)-cornstarch, CAS-sucrose. Rats fed 
SPI-cornstarch showed lower total body energy and 
fat gains compared with animals fed with the other 
diet combinations of either, CAS-cornstarch, 
CAS-sucrose, or SPI-sucrose. Plasma glucose and in-
sulin concentrations were also significantly lower in 
SPI-cornstarch diet than in those fed the CAS-sucrose 
diet. The reducing effect of SPI-cornstarch diet on 
body fat gain may be related to reductions in energy 
intake and in plasma glucose concentrations. Similarly, 
Lavigne et al evaluated the effects of feeding various 
types of dietary protein on glucose tolerance and insu-
lin sensitivity in rats [20]. Male Wistar rats were fed 
isoenergetic diets containing either casein, cod protein, 
or soy protein for 28 days. Cod protein-fed and soy 
protein-fed rats showed lower fasting plasma glucose 
and insulin concentrations compared with casein-fed 
animals. After an intravenous glucose load (1.5 ml/kg 
body wt of a 85% glucose in saline), cod protein-fed 
and soy protein-fed rats also showed lower incre-
mental areas under glucose curves compared with 
casein-fed animals, suggesting that cod and soy pro-
teins improve glucose tolerance. Additionally, higher 
glucose disposal rates were observed in cod pro-
tein-fed and soy protein-fed rats as compared with 
casein-fed rats, indicating an improvement in periph-
eral insulin sensitivity. However, in the postprandial 
state, the lower plasma insulin concentrations ob-
served in cod protein-fed and soy protein-fed animals 
may be due to decreased pancreatic insulin release 
and/or increased hepatic insulin removal. Recently, 
Davis et al evaluated effects of casein and soy protein 
on body weight, plasma cholesterol, and insulin sensi-
tivity in male lean SHHF (+/cp) rats, a unique rodent 
model that exhibits the early features resembling the 
metabolic syndrome in humans [21]. Rats fed soy pro-
tein (with either low or high isoflavone content) for 36 
weeks had significantly lower body weight, liver 
weight, total plasma cholesterol, fasting blood glucose, 
and plasma insulin, compared to rats fed casein.   
In a short-term study in humans, Anderson et al 
have shown that whey protein has a greater suppres-
sive effect on food intake than soy protein or egg al-
bumin [22]. These results differ from those obtained 
by Lang and co-workers [23] in their studies which 
compared the effects of six different proteins (egg al-
bumin, casein, gelatin, soy protein, pea protein, and 
wheat glutein) in a mixed meal on satiety in healthy 
human subjects. In this study, food intake and satiety 
was evaluated at 8- and 24-hour post-meal. These in-
vestigators found no differences between the different 
proteins on satiety and 24-hour energy or macronu-
trient intakes or on post-prandial glucose and insulin 
concentration. The reasons for these discrepant results 
are not clear. But they may relate to differences in the 
experimental design, other macronutrient composition 
of the diets, and duration of the dietary intervention. 
Nonetheless, the weight of the evidence suggests that 
consumption of plant-based protein, particularly soy 
protein, may suppress food intake and increase satiety 
and/or energy expenditure that may reduce body fat Int. J. Med. Sci. 2007, 4 
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gain and result in weight reduction, effects that may 
be useful for the prevention and treatment of obesity.     
3.  Nutrient composition of soy protein 
  Soybeans provide one of the most abundant 
plant sources of dietary protein. The protein content of 
soybeans varies from 36% to 56% [24-27]. Protein con-
tent of soybean from different areas are quantitatively 
different with those grown in the southern United 
States having high concentration of crude protein [24]. 
Differences in crude protein and amino acid composi-
tion of soybeans exist both within and among coun-
tries [25]. The predominant proteins in soybean are the 
storage proteins, namely 7S globulin (conglycinin) and 
11S globulin (glycinin), which comprise approxi-
mately 80% of the total proteins [26]. Other storage 
proteins are 2S, 9S, and 15S, which are present in 
much lesser amounts in soy protein. In addition, soy-
bean also contains lectin and protease inhibitors such 
as Kuntz and Bowman Burk [27].   
  Soy protein is considered a complete protein in 
that it contains most of the essential amino acids that 
are found in animal proteins. The nutritional value of 
soy protein is roughly equivalent to that of animal 
protein of high biological value [28]. For example, iso-
lated soy protein has a protein digestibility-corrected 
amino acid score of 1.0, which is the same as that of 
casein and egg protein [28]. However, soy proteins 
contain low methionine/glycine and lysine/arginine 
ratios compared to casein [29].   
  Soy protein is also associated with fatty acids, 
saponins, isoflavones and phospholipids. On a 
weight/weight basis, fatty acids comprise the largest 
group of chemicals in the soy protein isolate (SPI) fol-
lowed by saponins and then isoflavones. Although 
phospholipids are incorporated primarily in soybean 
oil, these compounds are present in smaller amounts 
in soy protein. SPI contains mainly lysophospholipids, 
the two major ones being lysophosphatidylcholines 
and lysophosphatidylethanolamines [30]. Soyasapon-
ins are one of the major classes of phytochemicals 
present in soy. The primary saponins found in soy-
beans are group A and group B soyasaponins with 
their precursors or aglycones, soyasapogenols A and B, 
respectively. The content of group B soyasaponins in 
whole soybean seeds is about four fold higher than 
group A saponins [31]. Saponin content in different 
varieties of soybeans range from 13-42 µmol/g in the 
germ and from 3-6 µmol/g in the cotyledon [32].   
Soy protein is unique among the plant-based 
proteins in that it is the only plant protein that con-
tains the largest concentrations of isoflavones. The 
amount of isoflavones in soybeans varies depending 
upon the type of soybean, geographic area of cultiva-
tion, and harvest years of soybeans [33-36]. In addition, 
isoflavone contents in different soy products also vary 
substantially due to differences in methods of proc-
essing [34]. Soybeans and commercially available soy 
products contain approximately 0.1-5 mg isofla-
vones/g protein; one serving of traditional soy foods 
provides about 0.25-40 mg isoflavones [33,36]. Soy 
products that contain most of the bean, such as mature 
soybeans, roasted soybeans, soy flour, and textured 
soy protein provide the highest concentrations of 
isoflavones, 0.1-5 mg total isoflavones/g soy protein 
[35]. Isolated soy protein and other soy protein prod-
ucts, such as tofu and soy milk, provide about 0.1-2 
mg isoflavones/g soy protein. Green soybeans and 
tempeh are intermediate sources of isoflavones, pro-
viding about 0.3 mg/g soy protein. Alcohol-extracted 
products, such as soy protein concentrate, contain 
relatively much lower amounts with values of < 0.3 
mg isoflavones/g soy protein.   
4.  Effect of dietary soy protein in animals and 
humans with obesity 
A number of studies in animals and humans 
suggest that consumption of soy protein have favor-
able effects on obesity and lipid metabolism. 
Animal Studies  
The studies on the effect of soy protein in animal 
models of obesity are summarized in Table 1. Iritani 
and co-workers [37] studied the effects of dietary soy 
protein on body weight, plasma and liver triacylglyc-
erol concentrations, and lipogenic enzyme gene ex-
pression in livers of genetically obese Wistar fatty rats. 
Wistar fatty rats and their lean littermates were fed 
casein or soy protein isolate diet containing hydro-
genated fat (4% hydrogenated fat plus 1% corn oil) or 
corn oil (5%) for 3 weeks. After 3 weeks of feeding, the 
fatty rats fed soy protein had lower body weight than 
those fed casein. Similarly, plasma and liver triacyl-
glycerol concentrations were also lower in soy pro-
tein-fed fatty and lean rats than in those fed casein. 
Moreover, the hepatic messenger RNA concentrations 
and activities of lipogenic enzymes were found to be 
lower in rats fed soy protein than in those fed casein, 
regardless of genotype or dietary fat. Using the same 
rodent model, the same group of investigators further 
examined the effects of different dietary fatty acids 
and proteins on glucose tolerance and insulin receptor 
gene expression in male Wistar fatty rats [38]. In this 
study, obese rats and their lean littermates (8 wk old) 
were fed a casein or soy protein diet containing 9% 
partially saturated beef tallow (plus 1% corn oil), 10% 
corn oil or 10% fish oil for 3 wk. In glucose tolerance 
tests, plasma insulin concentrations were significantly 
higher in obese rats fed corn oil or fish oil than in 
those fed partially saturated beef tallow, particularly 
in the soy protein groups. However, plasma glucose 
concentrations were not significantly affected by die-
tary protein or fat. The insulin receptor mRNA con-
centrations in livers and adipose tissues were higher 
in rats fed soy protein/partially saturated beef tallow 
than in those fed any other protein/fat combination. 
Thus, dietary soy protein appears to have anti-obesity 
effects and may also reduce insulin resistance, but 
only when a diet low in polyunsaturated fatty acids is 
consumed. Int. J. Med. Sci. 2007, 4 
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Table 1. Effects of dietary soy protein in animal models of obesity.  
Model    Diet and Amount    Duration    Effects   References  
 
Obese Wistar fatty rats 
 
soybean protein isolate vs casein   
 
3 wks   
 
Decreased BW, and plasma and liver 
triacylglycerols, decrease activity of li-
pogenic enzymes   
 
36 
Male Wistar fatty rats    Soybean protein isolate vs casein  3 wks    Increased insulin receptor mRNA in liver 
and adipose tissues, decreased insulin 
resistance  
37 
Dietary obese male Spra-
gue-Dawley rats and Obese 
yellow KK mice   
Soy protein isolate and hydrolysate 
vs casein protein, 35 % high-protein, 
5% low-fat 
2 wks  Decreased body fat and plasma glucose 
in mice 
38 
Genetically obese mice  Soy protein isolate and hydrolysate 
vs milk whey protein isolate and 
hydrolysate  
2 wks  Decreased BW and perirenal fat  39 
Obese KK-Ay mice    Soy protein isolate vs casein protein, 
isocaloric 15g, 100g diet   
  Decreased BW, bodyfat content, mesen-
teric, epididymal, and brown fat weight 
40 
Zucker fa/fa rats    Soybean protein diet isolate vs 
casein  
Life-time  Prevented hyperphagia, prolonged sur-
vival 
41 
Zucker fa/fa rats    Soybean protein diet vs casein  160 days  Decreased lipogenesis, decreased 
SERBP-1 and FAS   
60 
 
In another study, Aoyama et al compared the ef-
fects of an energy-restricted, low-fat (5%) and 
high-protein (35%) diet with either soy protein isolate 
(SPI) and its hydrolysate (SPI+H) or casein in male 
Sprague-Dawley rats made obese by feeding high-fat 
diets containing 30% fat and in genetically obese yel-
low KK mice [39]. They showed that body fat content 
and plasma glucose levels were significantly lower in 
mice fed SPI and SPI+H diets than in those fed casein. 
In rats, plasma total cholesterol level was lower with 
the SPI+H diet than with the casein diet. This study 
indicates that SPI and SPI+H are suitable protein 
sources in energy-restricted diets for the treatment of 
obesity. SPI and its hydrolysate also decreased body 
weight and perirenal fat pads compared to whey pro-
tein isolate [40].   
  Nagasawa et al. [41] evaluated the effects of a 
calorie-restricted diet containing soy protein isolate 
(SPI) on body fat composition, plasma glucose, lipid 
and adiponectin levels and expression of genes in-
volved in glucose and fatty acid metabolism in obese 
male KK-A y mice. Body weights and adipose tissue 
weights of mesenteric, epididymal, and brown fat 
were lower in mice on SPI diet. Plasma cholesterol, 
triglyceride, FFA, and glucose levels were also de-
creased by the SPI diet. Body fat content and plasma 
glucose levels in mice on a SPI diet were still lower 
than those treated with an isocaloric casein protein 
diet. Among the genes related to glucose and fatty 
acid metabolism, adiponectin mRNA levels in adipose 
tissue and adiponectin plasma concentrations were 
elevated in mice on a calorie-restricted diet, but there 
were no significant differences between soy protein 
and casein protein groups. These investigators con-
cluded that that soy protein diet decreased body fat 
content and plasma glucose levels more effectively 
than isocaloric casein protein diet in obese mice. 
 In a longevity study of Zucker obese (fa/fa) and 
lean (Fa/Fa) rats, Johnson et al showed that them 
feeding a soy protein diet ad libitum from 4 weeks of 
age remarkably prolonged their survival [42]. More-
over, pair-feeding obese Zucker rats with lean control 
rats prevented hyperphagia (with 8-18% restriction in 
energy intake) and also increased maximum life span, 
effects that were seen in both male and female animals. 
Interestingly, the percentage of body fat in 
food-restricted obese rats did not differ from that in 
animals fed ad libitum, suggesting that the protective 
effect of soy protein is not entirely related to adiposity 
per se.   
Human studies 
  Thus far, there have been only limited data re-
garding the long-term effects of dietary soy protein on 
obesity in humans (Table 2). In a short-term random-
ized single-blind study, Mikkelsen and coworkers 
compared the effects of fat-reduced diets containing 
either pork-meat protein, soy protein, and carbohy-
drate on 24-h energy expenditure in 12 young over-
weight and mildly obese men (body mass index = 
26-32) [43]. Diets were isoenergetic: pork diet (29% of 
energy as fat and 29% as protein); soy diet (29% of en-
ergy as fat and 28% as protein); and carbohydrate diet 
(28% of energy as fat and 11% as protein) and were 
administered for 4 days in a 3-way crossover design. 
After 4 days of each dietary intervention, 24-h energy 
expenditure measured in a respiratory chamber was 
significantly higher with the pork or soy diet than the 
carbohydrate diet. However, the animal protein diet 
produced a higher 24-h energy expenditure than the 
soy protein diet. These results indicated that both 
animal and soy protein have a greater thermogenic 
effect than carbohydrate, which may be relevant for 
the prevention and treatment of obesity.  
  Similarly, Bosello et al evaluated the short- and 
long-term effects of hypocaloric diets containing pro-
teins from different sources on body weight and 
plasma lipids in obese subjects [44]. In this study, 24 
obese patients, aged 25-42 yrs, of at least 50% above 
ideal weight, were divided into two groups: one 
group received casein and the other group, soy pro-
tein. Both diets were hypocaloric and contained the 
same amount of protein. The subjects initially received 
375 kcal/day for the first 15 days, followed by 425 
kcal/day for the succeeding 60 days. All subjects lost 
weight but the reduction in body weight was similar Int. J. Med. Sci. 2007, 4 
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in both groups. Total plasma cholesterol, VLDL cho-
lesterol, and LDL cholesterol decreased significantly 
in both groups after the two periods of caloric restric-
tion, but the percent changes were greater in the soy 
protein group than in the casein group. Plasma 
triglyceride was reduced in subjects that received soy 
protein but not in the group that received casein. 
These results show that substitution of soy protein can 
be of benefit in obese patients who need a long-term 
hypocaloric diet. In a randomized study of paral-
lel-design, Yamashita et al compared the effects of a 
meat-based diet with a plant-based diet in 36 over-
weight or obese women, age 40+9 yrs [45]. Both diets 
were designed to provide similar energy intake but 
one contained red meat and the other soybeans as the 
major protein source. After 16 weeks on the diet, sub-
j e c t s  i n  b o t h  d i e t  g r o u p s  l o s t  w e i g h t  ( 9 %  o f  b o d y  
weight) and showed similar decreases in plasma total 
cholesterol, LDL cholesterol, triacylglycerol and leptin 
levels. Interestingly, there was a significant reduction 
in the waist-to-hip ratio in both groups of subjects, 
suggesting that the weight loss induced by both diets 
was due in part to a decrease in abdominal fat.  
Table 2. Effects of dietary soy in obese humans  
Disease    Diet and Amount  Duration  Effects References   
 
Overweight and 
mildly obese men   
(N=12) 
 
Soydiet with 28-29% of energy as protein 
vs pork diet and carbohydrate diet 
 
4 days 
 
Lower 24-hr energy expenditure with soy than 
with pork diet   
 
42 
Obese subjects   
(N=24) 
Hypocaloric diet with soy protein vs 
hypocaloric diet with casein, 375 Kcal/d 
for 15 days, 426 kcal/d   
60 day  Decreased BW in both diets but greater reduc-
tions in total cholesterol, VLDL and LDL cho-
lesterol, and triglyceride 
43 
Obese women   
(N=36) 
Low-energy diet with soybeans vs low 
energy diet with lean meat   
16 wks    decrease in BW (9%) in both diets with similar 
reductions in plasma lipid and leptin levels   
44 
Obese subjects   
(N=100) 
Soy-based meal replacement formula 
(240g/day, 1200 kcal/day) vs control 
diet  
12 wks  Greater weight loss, greater reductions in body 
fat mass and total and LDL cholesterol 
45 
Pre-obese subjects   
(N=90) 
Lifestyle education, high soy protein diet 
w or w/o physical activity   
6 mos  All 3 interventions reduced BMI, greater de-
crease in BW and fat mass with physical activity 
46 
Overweight and 
obese women   
(N=90) 
Milk-based meal replacement (MR) vs 
soy-based MR in low energy diets 
12 wks  Modest weight loss, greater reductions in total 
and LDL cholesterol and triglyceride levels with 
soy MR than with milk MR 
47 
N = number of subjects; BW = body weight 
 
  Allison et al [46] performed a 12-week random-
ized controlled trial of a low calorie soy-based meal 
replacement program in 100 obese subjects. Subjects 
were randomized to either the meal replacement 
treatment group (240 g/day, 1200 kcal/day) or control 
group for a duration of 12 weeks. Subjects treated with 
the soy-based meal replacement formula lost more 
weight (7.0 vs 2.9 kg) and significantly greater reduc-
tions in body fat mass and in total cholesterol and 
LDL cholesterol than the control subjects. For any 
given degree of weight loss, the reduction in LDL 
cholesterol appeared to be greater in the treatment 
group.   
  In a randomized controlled trial, Deibert et al. 
[47] compared the effects of three different interven-
tions containing lifestyle education (LE-G) or a sub-
stitutional diet containing high-soy protein low-fat 
diet with (SD/PA-G) or without (SD-G) a guided 
physical activity program in 90 pre-obese and obese 
subjects with a mean body mass index (BMI) of 51.5. 
Subjects were randomly assigned to one of three in-
terventions for 6 months. All 3 interventions signifi-
cantly reduced BMI by about 2-3 kg/m2. However, 
subjects treated with SD-G and SD/PA-G lost more 
weight and had a greater decrease in body fat mass 
than those treated with LE-G. By contrast, no signifi-
cant differences were observed in lean body mass be-
tween the three treatment groups. This study indi-
cated that a high-soy protein and low-fat diet can im-
prove body composition and produce greater losses in 
body weight and fat mass without losing muscle mass 
in overweight and obese individuals.   
  In a 12-week randomized trial of obese subjects, 
Anderson and Hoie compared the effects of soy- ver-
sus milk-based meal replacements (MR) in overweight 
and obese women (BMI of 27-40 kg/m2) who con-
sumed low-energy diets (LED). Subjects were ran-
domly assigned to LED provided 1200kcal/day, with 
consumption of five soy-based or two milk-based liq-
uid MR for 12 weeks [48]. Subjects who consumed 
soy-MR had greater weight loss than those who con-
sumed milk-MR ((9.0 % vs7.9%) but the difference was 
not statistically significant. However, there were sig-
nificantly greater reductions total cholesterol, LDL 
cholesterol and triglyceride levels with soy-MR than 
with milk-MR. This study indicated that the use of a 
soy- based liquid meal replacement in a low-energy 
diet induced modest weight loss, that was associated 
with significant reduction in blood lipids. 
5.  Mechanisms of actions of soy protein 
The mechanisms whereby soy protein may exert 
its beneficial effects on obesity are not completely 
clear. Several lines of evidence suggest that soy pro-
tein may favorably affect lipid absorption, insulin re-
sistance, fatty acid metabolism, and other hormonal, 
cellular, or molecular changes associated with adipos-
ity.   
  It is well established that soy protein consump-
tion reduces serum total cholesterol, LDL cholesterol, 
and triglycerides as well as hepatic cholesterol and 
triglycerides. Studies in animals indicate that soy pro-
tein ingestion exerts its lipid-lowering effect by re-Int. J. Med. Sci. 2007, 4 
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ducing intestinal cholesterol absorption and increas-
ing fecal bile acid excretion, thereby reducing hepatic 
cholesterol content and enhancing removal of LDL 
(49,50). Dietary soy protein has also been shown to 
directly affect hepatic cholesterol metabolism and LDL 
receptor activity [51-53]. For example, Lovati and 
co-workers [51] demonstrated an increased binding of 
VLDL to liver membranes of hypercholesterolemic 
rats fed a diet containing soy protein, suggesting al-
tered hepatic metabolism with increased LDL and 
beta-VLDL removal by hepatocytes. Another study by 
Lovati et al have shown that soy protein diet consis-
tently increased degradation of LDL by mononuclear 
cells from patients with hypercholesterolemia, even in 
the presence of an elevated cholesterol intake [52]. 
Additional support for an effect of soy protein on LDL 
receptor activity was provided by Kirk et al. [53] in 
their studies using the LDL-receptor deficient 
(LDLr-null) mouse. In this study, significant reduc-
tions in plasma concentrations of total cholesterol, 
LDL-C, and VLDL-C were observed in C57BL/6J 
(wild type) mice fed soy protein isolate. By contrast, 
no significant effect of the soy protein isolate on 
plasma lipids was observed in LDLr-null mice, sug-
gesting that soy isoflavones might reduce lipid levels 
by increasing LDL receptor activity. Earlier work in 
humans with normal and elevated serum cholesterol 
has also shown that dietary soy protein reduces insu-
lin/glucagon ratio, which may contribute to the hy-
pocholesterolemic effect of soy protein [54]. More re-
cently, Gudbrandsen et al have shown that feeding 
obese Zucker rats with soy protein concentrate en-
riched with isoflavones (HDI) for 6 weeks reduced 
fatty liver and decreased the plasma levels of alanine 
transaminase and aspartate transaminase [55]. These 
effects were accompanied by increased activities of 
mitochondrial and peroxisomal beta-oxidation, ace-
tyl-CoA carboxylase, fatty acid synthase and glyc-
erol-3-phosphate acyltransferase in liver, increased 
plasma triacylglycerol level, and decreased hepatic 
mRNA level of VLDL receptor. However, the de-
creased gene expression of VLDL receptor found in 
the liver was not observed in epididymal fat and 
skeletal muscle of rats fed HDI, indicating that the 
liver may be the primary organ responsible for the 
reduced clearance of triacylglycerol-rich lipoproteins 
from plasma after HDI feeding. Thus, soy protein ap-
pears to exert its cholesterol-lowering action through 
different mechanisms that modulate cholesterol ab-
sorption and metabolism.   
  There is in-vivo evidence that soy protein may 
influence lipogenesis in the liver. In studies of rats, 
Iritani et al have shown that dietary soybean protein 
reduced the concentrations of triglycerides in plasma 
and especially in liver [56]. These effects were associ-
ated with marked reductions in the activities of he-
patic lipogenic enzymes, particularly glu-
cose-6-phosphate dehydrogenase, malic enzyme, fatty 
acid synthetase, as well as acetyl-CoA carboxylase 
(ACC) [56], suggesting that soy protein reduces liver 
triglycerides or fat by partly inhibiting hepatic fatty 
acid synthesis in the liver. ACC, the rate-limiting en-
zyme that catalyzes the carboxylation of acetyl-Co A 
to form malonyl-CoA, is the pivotal enzyme in the 
biosynthesis of long-chain fatty acids [57]. Recently, 
dietary SPI has also been shown to reduce the expres-
sion of ACCa and ACCb isoforms mRNA and protein 
contents in the liver of rats [58]. This action of SPI ap-
pears to be tissue-specific since the suppressive effect 
on ACC isoform gene expression was observed only 
in the liver but not in the heart or kidney. Furthermore, 
the ratios of phospho-ACCa/ACCa and pho-
pho-ACCb/ACCb were unchanged by SPI, suggesting 
that regulation of ACC by SPI was primarily mediated 
through alteration of its gene expression rather than 
phosphorylation or dephosphorylation. A similar re-
d u c t i o n  o f  h e p a t i c  A C C a  m R N A  e x p r e s s i o n  b y  s o y  
protein was also found in another study by Aoki et al 
[59] in which rats were fed SPI diet. In this study, SPI 
also reduced the expression of promoter I (PI) specific 
gene expression of ACCa, suggesting that SPI feeding 
suppresses ACCa gene expression mainly by regulat-
ing PI promoter. 
There is also experimental evidence that suggests 
that soy protein improves insulin resistance and lipid 
levels by activating peroxisome-proliferator activated 
receptors (PPARs), which are nuclear transcription 
factors that regulate the expression of genes involved 
in glucose homeostasis, lipid metabolism, and fatty 
acid oxidation [60,61]. Mezei et al showed that con-
sumption of high-isoflavone soy protein diet improves 
glucose tolerance, insulin resistance, and hepatic cho-
lesterol and triglyceride concentrations in obese 
Zucker rats [60]. In cell culture studies, these investi-
gators further showed that isoflavone-containing soy 
extracts and individual soy isoflavones increased the 
gene expression of PPARs, suggesting that the benefi-
cial effects of soy protein on glucose and lipid metabo-
lism may be mediated through PPAR activation. More 
r e c e n t l y ,  M o r i f u j i  e t  a l  [ 6 1 ]  d e m o n s t r a t e d  t h a t  s o y  
protein feeding in rats decreased hepatic triacylglyc-
erol levels and epididymal adipose tissue weight. 
These changes were associated with increased activity 
and mRNA levels of several skeletal muscle enzymes 
involved in fatty acid oxidation, including carnitine 
palmitoyltransferase (CPT1) activity and CPT1, 
beta-hydroxyacyl-CoA dehydrogenase (HAD), 
acyl-CoA oxidase, and medium-chain acyl-CoA de-
hydrogenase. Moreover, PPAR gamma coactivator 1 
alpha (PGC1 alpha) PGC1 alpha and PPAR alpha 
mRNA levels were also found to be elevated, sug-
gesting that soy protein intake stimulates skeletal 
muscle fatty acid oxidation by activating PPAR path-
ways leading to reduced accumulation of body fat. 
 Soy protein may reduce adiposity by modulating 
the expression of sterol regulatory element binding 
proteins (SREBPs), a family of transcription factors 
that controls multiple genes involved in fatty acid and 
cholesterol synthesis. In obese Zucker fa/fa rats, soy 
protein feeding was shown to reduce the expression of 
the hepatic SREBP-1 (the principal regulator of hepatic 
fatty acid biosynthesis) and its target genes – fatty acid Int. J. Med. Sci. 2007, 4 
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synthase (FAS), steroyl-CoA-desaturase-1, and delta-5 
and delta-6 desaturases [62]. In addition, the soy pro-
tein diet also ameliorated fatty liver and markedly re-
duced hepatic cholesterol and triglyceride  content, 
despite the fact that the rats were severely hyperinsu-
linemic. These findings suggest that soy protein con-
sumption downregulates hepatic SREBP-1 expression 
through an insulin-independent mechanism. In con-
trast to the changes in the liver, PPAR gamma (nuclear 
hormone receptor involved in normal adipocyte dif-
ferentiation) mRNA expression in adipose tissue was 
increased in obese rats fed soy protein. Histological 
analysis of epididymal adipose tissue from rats fed the 
soy protein revealed that there were more adipocytes 
per area but they were smaller in size than those fed 
casein. Taken together, these findings suggest that soy 
protein intake may limit adiposity by reducing the 
number of dysfunctional adipocytes possibly as a re-
sult of low lipogenesis. Soy protein may also reduce 
hepatic lipotoxicity by maintaining the number of 
functional adipocytes, preventing the transfer of fatty 
acids to extra adipose tissues.   
  Another possible mechanism of action of soy 
protein is via stimulation of adiponectin, a cytokine 
produced by fat cells that plays a key role in regulat-
ing in adipocyte differentiation and secretory function, 
and in enhancing insulin sensitivity [63-65]. Plasma 
levels of this hormone are reduced in obesity [66,67]. 
There is one report showing that dietary SPI intake is 
associated with increased plasma concentration of 
adiponectin in Wistar rats [68], suggesting that soy 
protein may modulate adiponectin production.   
  Which component(s) in soy protein is (are) re-
sponsible for its hypolipidemic and antiobesity effects 
is not entirely clear. Because soy protein contains 
many bioactive compounds or nutrients that may 
have multiple mechanisms of actions, it is difficult in 
nutritional intervention trials to disentangle the effect 
of any one constituent on lipid or body fat reduction. 
There are, however, in-vivo and in-vitro studies in 
which the effects of an isolated component or a single 
compound of soy protein on lipids have been exam-
ined.   
  Certain polypeptides or subunits of soy protein 
have been shown to mimic some of the effects of die-
tary soy protein on food intake and lipid metabolism. 
For example, in Sprague Dawley rats, oral administra-
tion of the soybean β-conglycinin peptone suppresses 
food intake and gastric emptying [69]. These effects 
were attributed in part to an increase in circulating 
levels of cholecystokinin. Similarly, in rats fed a hy-
percholesterolemic diet, ingestion of the alpha subunit 
of the soy 7S globulin (conglycinin) produced sub-
stantial reductions in plasma lipids as well as a 
marked upregulation of liver beta-VLDL receptors 
[70]. A soybean β-conglycinin diet was also shown to 
lower serum triglyceride, glucose, and insulin levels in 
normal and genetically obese (KK-Ay) mice [71]. 
These effects were accompanied by reduced hepatic 
fatty acid synthase activity and increased activities of 
two enzymes related to fatty acid beta-oxidation and 
mRNA of acyl-CoA oxidase levels, as well as in-
creased fecal excretion of tryglycerides, indicating that 
soy  β-conglycinin reduces serum TG levels by sup-
pression of hepatic fatty acid synthesis, acceleration of 
beta-oxidation, and/or increased TG fecal excretion 
[71].   
  Soyasaponins have been reported to reduce se-
rum cholesterol [72] but their role in fatty acid me-
tabolism is unknown. In a recent study of golden Syr-
ian hamsters, a diet containing group B soyasaponins 
(with no isoflavones) was shown lower plasma total 
cholesterol, non-HDL cholesterol, triglycerides, and 
the ratio of total cholesterol to HDL-cholesterol [73]. 
These changes were associated with increased fecal 
excretion of bile acids and neutral sterols, suggesting 
that group B soyasaponins reduces plasma lipids by a 
mechanism involving greater excretion of fecal bile 
acids and neutral sterols. Interestingly, an earlier re-
port showed that oral administration of total soyas-
aponins was also found to prevent the development of 
obesity and hyperinsulinemia induced by gold 
thioglucose injection in mice [74].   
  Phospholipids present in soy protein may be 
partly responsible for its antilipidemic effects. 
Short-term feeding with a diet containing soybean 
phospholipids for 3 days was shown to markedly re-
duce the activities of hepatic fatty acid synthetase, ma-
lic enzyme, glucose 6-phosphate dehydrogenase and 
pyruvate kinase in rats [75]. Compared to a fat-free 
diet or a diet containing soybean oil, the diet contain-
ing soybean phospholipids also markedly decreased 
the hepatic mRNA levels of enzymes in fatty acid 
synthesis. A greater reduction of serum cholesterol as 
well as total lipid and cholesterol concentrations in 
liver was also observed when rats were fed a soy pro-
tein peptic hydrolysate with bound phospholipids, 
compared to soy protein diet alone or soy protein hy-
drolysate [76]. 
  Part of the antiobesity effect of soy protein may 
be due to the presence of the isoflavones, since soy 
isoflavones have been shown to decrease fat accumu-
lation in certain fat depots in some animal models of 
obesity [77-79]. Additionally, work by Mezei et al [60] 
has shown that consumption of a high isofla-
vone-containing soy diet improves glucose tolerance 
and reduces liver triglyceride and cholesterol concen-
trations obese Zucker rats. Moreover, cell culture 
studies showed that isoflavone-containing soy extracts 
and individual soy isoflavones, genistein and daidzein 
upregulate PPARalpha and PPARgamme-mediated 
gene expression. Exposure to soy isoflavones was also 
shown increase the expressions of the mature form of 
SREBP-2 and SREBP-regulated genes in HepG2 cells 
[80]. Furthermore, exposure to soy isoflavones also 
increased HMG CoA reductase protein  levels and 
HMG CoA synthase mRNA levels and increased both 
HMG CoA synthase and LDL receptor promoter ac-
tivity, indicating that isoflavones may also regulate 
the genes involved in cholesterol biosynthesis and 
homeostasis.  
  Interestingly, in a recent study of agouti viable Int. J. Med. Sci. 2007, 4 
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yellow (Avy) mice, a genetic model that develops hy-
perinsulinemia, obesity, type 2 diabetes, and yellow 
fur, it was shown that dietary genistein supplementa-
tion of female mice during gestation at levels compa-
rable with those received by humans consuming 
high-soy diets, resulted in a shift in coat color of het-
erozygous mice and protected offsprings from devel-
oping obesity [81]. These marked phenotypic changes 
induced by dietary genistein appear to be mediated by 
increased DNA methylation in tissues during early 
embryonic development that persisted into adulthood.   
  Thus, certain polypeptides (such as 7S globulin 
or conglycinin), soyasaponins, phospholipids, and 
isoflavones (genistein and daidzein) present in soy-
bean appear to have complimentary actions on fatty 
acid and cholesterol metabolism, which may contrib-
ute to the overall beneficial effects of soy protein in 
obesity and associated lipid abnormalities.   
6.  Soy protein allergy 
  Soybean has long been implicated as a possible 
cause of food allergy [82] and is cited as one of the 8 
most common allergenic foods. This “group of 8” in-
cludes milk, eggs, fish, crustacea, wheat, peanuts, tree 
nuts, and soy, accounting for about 90% of food aller-
gies [83]. Soy protein allergy occurs only in a minority 
of children with food allergies and is relatively un-
common in adults [83-85]. For example, a 
meta-analysis of 17 different studies of allergen reac-
tivity in infants and children showed that soy allergy 
occurs in about 3–4% of subjects compared to 25% for 
allergy to cow’s milk [84]. There are also reports that 
soy protein has a lower allergenic potential when 
compared with other major food proteins [85]. In ad-
dition, studies comparing dose-response relationships 
of different food allergens for triggering allergic 
symptoms also demonstrate a much higher protein 
concentration threshold for soy protein than other 
food proteins [86]. In view of the lower allergic poten-
tial of soy protein, soy milk formulas have been 
widely used for the management of food allergy in 
infants and children.   
 The component in soy protein responsible for al-
lergic reactions is not completely certain but several 
potential soy protein allergens have been identified in 
a number of studies in soybean-sensitive patients 
These include include b-conglycinin, glycinin, soy 
vacuolar protein, Kunitz trypsin inhibitor, and other 
proteins [83,87-89]. Awazuhara et al detected IgE- and 
IgG4-binding proteins in soybean by immunoblotting 
with sera from 30 soybean-sensitive patients [88]. Ten 
proteins were detected as IgE-binding proteins and 8 
proteins as IgG4-binding proteins, with high IgE de-
tection rate and specificity. Among the IgE-binding 
proteins, the proteins with molecular weights of 
20,000 and 58,000 were found to be in the whey frac-
tion, and 26,000 and 31,000 were in the globulin frac-
tion. Five proteins were suggested as the major aller-
gens in the IgE-mediated reaction where as 
IgG4-binding proteins might act anaphylactically in 
patients with soybean allergy. Ogawa et al also 
showed that at least 15 soy protein allergens were 
recognized by sera of soybean-sensitive patients [89]. 
The three major the allergenic soy proteins found in 
these patients were Gly m Bd 60 K, Gly m Bd 30 K, 
and Gly m Bd 28 K. It has been shown that certain soy 
protein products can be made hypoallergenic by 
chemical treatment or by genetic modification by 
transgenic techniques [90,91]. For now, the only 
treatment available for soy protein allergy is avoid-
ance of soy-based protein products.   
7.  Summary and Conclusions 
  In conclusion, an increasing body of evidence 
from nutritional intervention studies in animals and 
humans indicates that dietary soy protein has benefi-
cial effects on obesity. Consumption of soy protein can 
favorably affect satiety and reduce excess body fat in 
obese animals and humans. Soy protein ingestion also 
improves insulin resistance, the hallmark of obesity. 
Dietary soy protein and some of its constituents also 
reduce plasma lipids and fat accumulation in liver and 
adipose tissue, which may reduce the risks of athero-
sclerosis and lipotoxicity and possibly other obe-
sity-related complications. Several potential mecha-
nisms whereby soy protein or its constituents may 
improve insulin resistance and lower body fat and 
blood lipids have been discussed and include a wide 
spectrum of biochemical and molecular activities that 
favorably affect energy balance and fat metabolism. 
Furthermore, in animal models of obesity, dietary soy 
protein and isoflavones appear to modulate the ex-
pression of nuclear transcription factors, namely 
PPARs and SREBPs, which are the principal regulators 
of fatty acid metabolism and cholesterol homeostasis. 
Thus far, clinical studies that have been conducted in 
obese humans are few and limited by the relatively 
short duration of the dietary interventions and the 
inclusion a small number of subjects. Ingestion of soy 
protein, like any food that contains protein, has to po-
tential to cause an allergic reaction and, therefore, 
should be avoided in high-risk individuals with food 
allergies. Long-term prospective randomized trials 
involving a large number of obese subjects are needed 
to confirm whether soy protein provides long-term 
safety and benefits in humans with obesity.   
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